Abstract: A carbon material for a non-aqueous secondary battery containing a graphite capable of occluding and releasing lithium ions, and having a cumulative pore volume at pore diameters in a range of 0.01 ?m to 1 ?m of 0.08 mL/g or more, a roundness, as determined by flow-type particle image analysis, of 0.88 or greater, and a pore diameter to particle diameter ratio (PD/d50 (%)) of 1.8 or less, the ratio being given by equation (1A): PD/d50 (%)=mode pore diameter (PD) in a pore diameter range of 0.01 ?m to 1 ?m in a pore distribution determined by mercury intrusion/volume-based average particle diameter (d50)×100 is provided.

Abstract: The invention relates to compositions and methods for inhibiting macrophage activation via modulating PARP9 and/or PARP14 expression or activity, such as small molecules, RNAi and antibodies.

Abstract: The invention relates to compositions and methods for inhibiting macrophage activation via modulating PARP9 and/or PARP14 expression or activity, such as small molecules, RNAi and antibodies.

Abstract: The invention relates to compositions and methods for inhibiting macrophage activation via modulating PARP9 and/or PARP14 expression or activity, such as small molecules, RNAi and antibodies. Modulating the expression and/or activity of PARP9 and/or PARP14 allows the inhibition of monocytes or macrophage M1 activation and inflammation. Inhibiting undesirable excessive or sustained inflammation found in humans, for the treatment, prevention and/or management of conditions where undesirable excessive or sustained inflammation is known or likely to contribute to the onset, development and/or progression the conditions.

Abstract: The invention relates to compositions and methods for inhibiting macrophage activation via modulating PARP9 and/or PARP14 expression or activity, such as small molecules, RNAi and antibodies. Modulating the expression and/or activity of PARP9 and/or PARP14 allows the inhibition of monocytes or macrophage M1 activation and inflammation. Inhibiting undesirable excessive or sustained inflammation found in humans, for the treatment, prevention and/or management of conditions where undesirable excessive or sustained inflammation is known or likely to contribute to the onset, development and/or progression the conditions.

Abstract: A method for manufacturing tubes filled with powdery and/or granular substances comprising the steps of forming a metal strip into a tube, feeding powdery and/or granular substances into the tube being formed as a core, joining together the edges of the tube filled with the core of the powdery and/or granular substances by high-frequency welding, and reducing the diameter of the welded tube filled with the core of the powdery and/or granular substances. At least the top layer of the core in the tube is composed of powdery and/or granular substances having low enough magnetic susceptibility to remain unattracted to the magnetized tube edges that is determined based on the welding heat input.

Abstract: A method of manufacturing tubes filled with powdery and/or granular substances, such as flux-cored welding wires. A tube filled with a powdery and/or granular substance is continuously manufactured by forming a metal strip being fed in its longitudinal direction into an unwelded tube (1a) using forming rolls (2), feeding a powdery and/or granular substance (F) into the unwelded tube (1a) being formed through its opening, butt-welding together fringing edges of the opening, and reducing the diameter of the welded tube (1b). An allowable minimum heat input below which cold cracking occurs and a maximum allowable heat input above which spatters whose diameter is not smaller than 0.83 times the inside diameter of the finished tube are generated are determined in advance, and the butt welding is performed with a heat input larger than the allowable minimum heat input and smaller than the allowable maximum heat input.